Study on GSK5458514 Alone or with Other Cancer Drugs for Prostate Cancer

Inclusion Criteria

• Must provide signed informed consent and be able to follow study requirements.
• Male participants aged 18 or older.
• Agree not to donate sperm and either remain abstinent or use contraception during the study and for 195 days after the last dose.
• Have metastatic castration-resistant prostate cancer (mCRPC) confirmed by medical tests.
• Have previously tried and not responded to certain prostate cancer treatments.
• Have at least one measurable tumor or specific signs of cancer progression.
• Have low testosterone levels and be on continuous hormone therapy.
• Be in good general health with a performance status of 0 or 1.
• Provide a tumor sample for research purposes.
• Have adequate organ function as shown by medical tests.

Exclusion Criteria

• Have a type of prostate cancer other than adenocarcinoma.
• Have cancer that has spread to the brain or spinal fluid.
• Have had another invasive cancer in the last 5 years, except for certain treated skin or bladder cancers.
• Have ongoing side effects from previous treatments that have not improved.
• Have a history of autoimmune disease requiring treatment in the last 2 years.
• Have lung disease or a history of lung inflammation.
• Have received certain cancer treatments recently.
• Have had a bone marrow or organ transplant.
• Have allergies to study drugs or components.
• Have severe neurological or psychiatric disorders.
• Have had major surgery recently.
• Have serious infections or liver problems.
• Have hepatitis B or C infections.
• Cannot follow study procedures or requirements.